On Wednesday, Centessa Pharma ADR received a positive adjustment to its Relative Strength (RS) Rating, from 70 to 75.
How To Invest In Stocks In Both Bull And Bear Markets
This exclusive rating from Investor's Business Daily tracks price performance with a 1 (worst) to 99 (best) score. The grade shows how a stock's price movement over the trailing 52 weeks holds up against all the other stocks in our database.
Decades of market research reveals that the top-performing stocks tend to have an 80 or better RS Rating in the early stages of their moves. See if Centessa Pharma ADR can continue to show renewed price strength and hit that benchmark.
While the stock is not near a proper entry right now, see if it manages to form and break out of a proper consolidation.
Centessa Pharma ADR showed 0% earnings growth last quarter, while sales growth came in at -100%. The company is expected to report its latest numbers on or around May 19.
The company earns the No. 20 rank among its peers in the Medical-Research Equipment/Services industry group. Veracyte, Natera and Schrodinger are among the top 5 highly rated stocks within the group.
This article was created automatically with Stats Perform's Wordsmith software using data and article templates supplied by Investor's Business Daily. An IBD journalist may have edited the article.
RELATED:
Stocks With Rising Relative Strength Ratings
Why Should You Use IBD's Relative Strength Rating?
How Relative Strength Line Can Help You Judge A Stock
Ready To Grow Your Investing Skills? Join An IBD Meetup Group!
